Novel . . O O
mutant . . B-Mutation B-Mutation
- . . O O
enriched . . O O
sequencing . . O O
identified . . O O
high . . O O
frequency . . O O
of . . O O
PIK3CA . . O O
mutations . . B-Mutation B-Mutation
in . . O O
pharyngeal . . O O
cancer . . O O
. . . O O

We . . O O
previously . . O O
reported . . O O
4 . . O O
PIK3CA . . O O
mutations . . B-Mutation B-Mutation
in . . O O
38 . . O O
head . . O O
and . . O O
neck . . O O
cancer . . O O
samples . . O O
, . . O O
3 . . O O
of . . O O
which . . O O
were . . O O
identified . . O O
in . . O O
6 . . O O
pharyngeal . . O O
cancer . . O O
samples . . O O
. . . O O

To . . O O
determine . . O O
the . . O O
mutation . . B-Mutation B-Mutation
frequency . . O O
of . . O O
PIK3CA . . O O
in . . O O
pharyngeal . . O O
cancer . . O O
, . . O O
we . . O O
studied . . O O
24 . . O O
additional . . O O
cases . . O O
of . . O O
pharyngeal . . O O
squamous . . O O
cell . . O O
carcinoma . . O O
in . . O O
this . . O O
study . . O O
. . . O O

Using . . O O
both . . O O
direct . . O O
genomic . . O O
DNA . . O O
sequencing . . O O
and . . O O
novel . . O O
mutant . . O B-Mutation
- . . O O
enriched . . O O
sequencing . . O O
methods . . O O
developed . . O O
specifically . . O O
for . . O O
the . . O O
3 . . O O
hot . . O O
- . . O O
spot . . O O
mutations . . B-Mutation B-Mutation
( . . O O
H1047R . . B-Mutation O
, . . O O
E545K . . B-Mutation O
and . . O O
E452K . . B-Mutation O
) . . O O
of . . O O
PIK3CA . . O O
, . . O O
we . . O O
detected . . O O
5 . . O O
mutations . . B-Mutation B-Mutation
of . . O O
PIK3CA . . O O
in . . O O
the . . O O
24 . . O O
pharyngeal . . O O
cancers . . O O
( . . O O
20 . . O O
. . . O O
8 . . O O
% . . O O
) . . O O
. . . O O

Three . . O O
of . . O O
the . . O O
5 . . O O
mutations . . B-Mutation B-Mutation
had . . O O
been . . O O
missed . . O O
by . . O O
the . . O O
conventional . . O O
sequencing . . O O
method . . O O
and . . O O
were . . O O
subsequently . . O O
detected . . O O
by . . O O
novel . . O O
mutant . . O B-Mutation
- . . O O
enriched . . O O
sequencing . . O O
methods . . O O
. . . O O

We . . O O
showed . . O O
that . . O O
the . . O O
mutant . . O B-Mutation
- . . O O
enriched . . O O
sequencing . . O O
method . . O O
for . . O O
the . . O O
H1047R . . B-Mutation O
hot . . O O
- . . O O
spot . . O O
mutation . . B-Mutation B-Mutation
can . . O O
identify . . O O
the . . O O
mutation . . B-Mutation B-Mutation
in . . O O
a . . O O
mixed . . O O
population . . O O
of . . O O
mutant . . B-Mutation B-Mutation
and . . O O
wild . . O O
- . . O O
type . . O O
DNA . . O O
sequences . . O O
at . . O O
1 . . O O
: . . O O
360 . . O O
ratios . . O O
. . . O O

These . . O O
novel . . O O
mutant . . O B-Mutation
- . . O O
enriched . . O O
sequencing . . O O
methods . . O O
allow . . O O
the . . O O
detection . . O O
of . . O O
the . . O O
PIK3CA . . O O
hot . . O O
- . . O O
spot . . O O
mutations . . B-Mutation B-Mutation
in . . O O
clinical . . O O
specimens . . O O
which . . O O
often . . O O
contain . . O O
limited . . O O
tumor . . O O
tissues . . O O
( . . O O
i . . O O
. . . O O
e . . O O
. . . O O
, . . O O
biopsy . . O O
specimens . . O O
) . . O O
. . . O O

The . . O O
data . . O O
further . . O O
support . . O O
that . . O O
oncogenic . . O O
PIK3CA . . O O
may . . O O
play . . O O
a . . O O
critical . . O O
role . . O O
in . . O O
pharyngeal . . O O
carcinogenesis . . O O
, . . O O
and . . O O
the . . O O
mutant . . O B-Mutation
- . . O O
enriched . . O O
sequencing . . O O
methods . . O O
for . . O O
PIK3CA . . O O
are . . O O
sensitive . . O O
and . . O O
reliable . . O O
ways . . O O
to . . O O
detect . . O O
PIK3CA . . O O
mutations . . B-Mutation B-Mutation
in . . O O
clinical . . O O
samples . . O O
. . . O O

Because . . O O
PIK3CA . . O O
and . . O O
its . . O O
pathway . . O O
are . . O O
potential . . O O
targets . . O O
for . . O O
chemotherapy . . O O
and . . O O
radiation . . O O
therapy . . O O
, . . O O
and . . O O
frequent . . O O
somatic . . O O
mutation . . B-Mutation B-Mutation
of . . O O
PIK3CA . . O O
has . . O O
been . . O O
identified . . O O
in . . O O
many . . O O
human . . O O
cancer . . O O
types . . O O
( . . O O
e . . O O
. . . O O
g . . O O
. . . O O
, . . O O
breast . . O O
cancer . . O O
, . . O O
colorectal . . O O
cancer . . O O
) . . O O
, . . O O
the . . O O
abilities . . O O
to . . O O
detect . . O O
PIK3CA . . O O
mutations . . B-Mutation B-Mutation
with . . O O
enhanced . . O O
sensitivities . . O O
have . . O O
great . . O O
potential . . O O
impacts . . O O
on . . O O
target . . O O
therapies . . O O
for . . O O
many . . O O
cancer . . O O
types . . O O
. . . O O

Complex . . O O
patterns . . O O
of . . O O
altered . . O O
MicroRNA . . O O
expression . . O O
during . . O O
the . . O O
adenoma . . O O
- . . O O
adenocarcinoma . . O O
sequence . . O O
for . . O O
microsatellite . . O O
- . . O O
stable . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
PURPOSE . . O O

MicroRNAs . . O O
are . . O O
short . . O O
noncoding . . O O
RNAs . . O O
that . . O O
regulate . . O O
gene . . O O
expression . . O O
and . . O O
are . . O O
over . . O O
- . . O O
or . . O O
underexpressed . . O O
in . . O O
most . . O O
tumors . . O O
, . . O O
including . . O O
colorectal . . O O
adenocarcinoma . . O O
. . . O O

MicroRNAs . . O O
are . . O O
potential . . O O
biomarkers . . O O
and . . O O
therapeutic . . O O
targets . . O O
and . . O O
agents . . O O
, . . O O
but . . O O
limited . . O O
information . . O O
on . . O O
microRNAome . . O O
alterations . . O O
during . . O O
progression . . O O
in . . O O
the . . O O
well . . O O
- . . O O
known . . O O
adenoma . . O O
- . . O O
adenocarcinoma . . O O
sequence . . O O
is . . O O
available . . O O
to . . O O
guide . . O O
their . . O O
usage . . O O
. . . O O

# . . O O
# . . O O
EXPERIMENTAL . . O O
DESIGN . . O O

We . . O O
profiled . . O O
866 . . O O
human . . O O
microRNAs . . O O
by . . O O
microarray . . O O
analysis . . O O
in . . O O
69 . . O O
matched . . O O
specimens . . O O
of . . O O
microsatellite . . O O
- . . O O
stable . . O O
adenocarcinomas . . O O
, . . O O
adjoining . . O O
precursor . . O O
adenomas . . O O
including . . O O
areas . . O O
of . . O O
high . . O O
- . . O O
and . . O O
low . . O O
- . . O O
grade . . O O
dysplasia . . O O
, . . O O
and . . O O
nonneoplastic . . O O
mucosa . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

We . . O O
found . . O O
230 . . O O
microRNAs . . O O
that . . O O
were . . O O
significantly . . O O
differentially . . O O
expressed . . O O
during . . O O
progression . . O O
, . . O O
including . . O O
19 . . O O
not . . O O
reported . . O O
previously . . O O
. . . O O

Altered . . O O
microRNAs . . O O
clustered . . O O
into . . O O
two . . O O
major . . O O
patterns . . O O
of . . O O
early . . O O
( . . O O
type . . O O
I . . O O
) . . O O
and . . O O
late . . O O
( . . O O
type . . O O
II . . O O
) . . O O
differential . . O O
expression . . O O
. . . O O

The . . O O
largest . . O O
number . . O O
( . . O O
n . . O O
= . . O O
108 . . O O
) . . O O
was . . O O
altered . . O O
at . . O O
the . . O O
earliest . . O O
step . . O O
from . . O O
mucosa . . O O
to . . O O
low . . O O
- . . O O
grade . . O O
dysplasia . . O O
( . . O O
subtype . . O O
IA . . O O
) . . O O
prior . . O O
to . . O O
major . . O O
nuclear . . O O
localization . . O O
of . . O O
β . . O O
- . . O O
catenin . . O O
, . . O O
including . . O O
36 . . O O
microRNAs . . O O
that . . O O
had . . O O
persistent . . O O
differential . . O O
expression . . O O
throughout . . O O
the . . O O
entire . . O O
sequence . . O O
to . . O O
adenocarcinoma . . O O
. . . O O

Twenty . . O O
microRNAs . . O O
were . . O O
intermittently . . O O
altered . . O O
( . . O O
subtype . . O O
IB . . O O
) . . O O
, . . O O
and . . O O
six . . O O
were . . O O
transiently . . O O
altered . . O O
( . . O O
subtype . . O O
IC . . O O
) . . O O
. . . O O

In . . O O
contrast . . O O
, . . O O
33 . . O O
microRNAs . . O O
were . . O O
altered . . O O
late . . O O
in . . O O
high . . O O
- . . O O
grade . . O O
dysplasia . . O O
and . . O O
adenocarcinoma . . O O
( . . O O
subtype . . O O
IIA . . O O
) . . O O
, . . O O
and . . O O
63 . . O O
in . . O O
adenocarcinoma . . O O
only . . O O
( . . O O
subtype . . O O
IIB . . O O
) . . O O
. . . O O

Predicted . . O O
targets . . O O
in . . O O
12 . . O O
molecular . . O O
pathways . . O O
were . . O O
identified . . O O
for . . O O
highly . . O O
altered . . O O
microRNAs . . O O
, . . O O
including . . O O
the . . O O
Wnt . . O O
signaling . . O O
pathway . . O O
leading . . O O
to . . O O
low . . O O
- . . O O
grade . . O O
dysplasia . . O O
. . . O O

β . . O O
- . . O O
catenin . . O O
expression . . O O
correlated . . O O
with . . O O
downregulated . . O O
microRNAs . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Our . . O O
findings . . O O
suggest . . O O
that . . O O
numerous . . O O
microRNAs . . O O
play . . O O
roles . . O O
in . . O O
the . . O O
sequence . . O O
of . . O O
molecular . . O O
events . . O O
, . . O O
especially . . O O
early . . O O
events . . O O
, . . O O
resulting . . O O
in . . O O
colorectal . . O O
adenocarcinoma . . O O
. . . O O

The . . O O
temporal . . O O
patterns . . O O
and . . O O
complexity . . O O
of . . O O
microRNAome . . O O
alterations . . O O
during . . O O
progression . . O O
will . . O O
influence . . O O
the . . O O
efficacy . . O O
of . . O O
microRNAs . . O O
for . . O O
clinical . . O O
purposes . . O O
. . . O O

Evolutionarily . . O O
conserved . . O O
protein . . O O
ERH . . O O
controls . . O O
CENP . . O O
- . . O O
E . . O O
mRNA . . O O
splicing . . O O
and . . O O
is . . O O
required . . O O
for . . O O
the . . O O
survival . . O O
of . . O O
KRAS . . O O
mutant . . B-Mutation B-Mutation
cancer . . O O
cells . . O O
. . . O O

Cancers . . O O
with . . O O
Ras . . O O
mutations . . B-Mutation B-Mutation
represent . . O O
a . . O O
major . . O O
therapeutic . . O O
problem . . O O
. . . O O

Recent . . O O
RNAi . . O O
screens . . O O
have . . O O
uncovered . . O O
multiple . . O O
nononcogene . . O O
addiction . . O O
pathways . . O O
that . . O O
are . . O O
necessary . . O O
for . . O O
the . . O O
survival . . O O
of . . O O
Ras . . O O
mutant . . B-Mutation B-Mutation
cells . . O O
. . . O O

Here . . O O
, . . O O
we . . O O
identify . . O O
the . . O O
evolutionarily . . O O
conserved . . O O
gene . . O O
enhancer . . O O
of . . O O
rudimentary . . O O
homolog . . O O
( . . O O
ERH . . O O
) . . O O
, . . O O
in . . O O
which . . O O
depletion . . O O
causes . . O O
greater . . O O
toxicity . . O O
in . . O O
cancer . . O O
cells . . O O
with . . O O
mutations . . B-Mutation B-Mutation
in . . O O
the . . O O
small . . O O
GTPase . . O O
KRAS . . O O
compared . . O O
with . . O O
KRAS . . O O
WT . . O O
cells . . O O
. . . O O

ERH . . O O
interacts . . O O
with . . O O
the . . O O
spliceosome . . O O
protein . . O O
SNRPD3 . . O O
and . . O O
is . . O O
required . . O O
for . . O O
the . . O O
mRNA . . O O
splicing . . O O
of . . O O
the . . O O
mitotic . . O O
motor . . O O
protein . . O O
CENP . . O O
- . . O O
E . . O O
. . . O O

Loss . . B-Mutation B-Mutation
of . . O O
ERH . . O O
leads . . O O
to . . O O
loss . . B-Mutation B-Mutation
of . . O O
CENP . . O O
- . . O O
E . . O O
and . . O O
consequently . . O O
, . . O O
chromosome . . O O
congression . . O O
defects . . O B-Mutation
. . . O O

Gene . . O O
expression . . O O
profiling . . O O
indicates . . O O
that . . O O
ERH . . O O
is . . O O
required . . O O
for . . O O
the . . O O
expression . . O O
of . . O O
multiple . . O O
cell . . O O
cycle . . O O
genes . . O O
, . . O O
and . . O O
the . . O O
gene . . O O
expression . . O O
signature . . O O
resulting . . O O
from . . O O
ERH . . O O
down . . O O
- . . O O
regulation . . O O
inversely . . O O
correlates . . O O
with . . O O
KRAS . . O O
signatures . . O O
. . . O O

Clinically . . O O
, . . O O
tumor . . O O
ERH . . O O
expression . . O O
is . . O O
inversely . . O O
associated . . O O
with . . O O
survival . . O O
of . . O O
colorectal . . O O
cancer . . O O
patients . . O O
whose . . O O
tumors . . O O
harbor . . O O
KRAS . . O O
mutations . . B-Mutation B-Mutation
. . . O O

Together . . O O
, . . O O
these . . O O
findings . . O O
identify . . O O
a . . O O
role . . O O
of . . O O
ERH . . O O
in . . O O
mRNA . . O O
splicing . . O O
and . . O O
mitosis . . O O
, . . O O
and . . O O
they . . O O
provide . . O O
evidence . . O O
that . . O O
KRAS . . O O
mutant . . B-Mutation B-Mutation
cancer . . O O
cells . . O O
are . . O O
dependent . . O O
on . . O O
ERH . . O O
for . . O O
their . . O O
survival . . O O
. . . O O

Noninvasive . . O O
testing . . O O
for . . O O
colorectal . . O O
cancer . . O O
: . . O O
a . . O O
review . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVES . . O O

Colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
is . . O O
the . . O O
second . . O O
leading . . O O
cause . . O O
of . . O O
cancer . . O O
- . . O O
related . . O O
death . . O O
in . . O O
the . . O O
United . . O O
States . . O O
. . . O O

Endoscopic . . O O
screening . . O O
is . . O O
now . . O O
in . . O O
favor . . O O
and . . O O
its . . O O
use . . O O
is . . O O
increasing . . O O
, . . O O
but . . O O
overall . . O O
participation . . O O
rates . . O O
are . . O O
poor . . O O
. . . O O

A . . O O
substantial . . O O
percentage . . O O
of . . O O
the . . O O
population . . O O
will . . O O
likely . . O O
continue . . O O
to . . O O
resist . . O O
endoscopic . . O O
screening . . O O
. . . O O

As . . O O
such . . O O
, . . O O
a . . O O
noninvasive . . O O
biomarker . . O O
for . . O O
the . . O O
early . . O O
detection . . O O
of . . O O
CRC . . O O
remains . . O O
a . . O O
priority . . O O
. . . O O

Herein . . O O
, . . O O
we . . O O
( . . O O
i . . O O
) . . O O
review . . O O
the . . O O
currently . . O O
available . . O O
noninvasive . . O O
screening . . O O
markers . . O O
for . . O O
the . . O O
early . . O O
detection . . O O
of . . O O
CRC . . O O
, . . O O
( . . O O
ii . . O O
) . . O O
discuss . . O O
newer . . O O
markers . . O O
that . . O O
have . . O O
undergone . . O O
preliminary . . O O
testing . . O O
, . . O O
and . . O O
( . . O O
iii . . O O
) . . O O
introduce . . O O
and . . O O
explain . . O O
potentially . . O O
promising . . O O
markers . . O O
of . . O O
the . . O O
future . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

The . . O O
published . . O O
literature . . O O
on . . O O
markers . . O O
for . . O O
early . . O O
detection . . O O
of . . O O
CRC . . O O
was . . O O
identified . . O O
using . . O O
a . . O O
MEDLINE . . O O
/ . . O O
PubMed . . O O
search . . O O
with . . O O
secondary . . O O
review . . O O
of . . O O
cited . . O O
publications . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Noninvasive . . O O
testing . . O O
for . . O O
CRC . . O O
is . . O O
most . . O O
advanced . . O O
in . . O O
testing . . O O
for . . O O
stool . . O O
fecal . . O O
occult . . O O
blood . . O O
, . . O O
globin . . O O
, . . O O
or . . O O
DNA . . O O
mutations . . B-Mutation B-Mutation
. . . O O

Study . . O O
of . . O O
abnormal . . O O
mucins . . O O
has . . O O
also . . O O
been . . O O
explored . . O O
. . . O O

Research . . O O
for . . O O
serum . . O O
- . . O O
based . . O O
markers . . O O
is . . O O
just . . O O
beginning . . O O
and . . O O
includes . . O O
serum . . O O
proteomics . . O O
, . . O O
nuclear . . O O
matrix . . O O
proteins . . O O
, . . O O
and . . O O
serum . . O O
DNA . . O O
testing . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Serial . . O O
guaiac . . O O
- . . O O
based . . O O
fecal . . O O
occult . . O O
blood . . O O
testing . . O O
( . . O O
FOBT . . O O
) . . O O
is . . O O
simple . . O O
, . . O O
inexpensive . . O O
, . . O O
and . . O O
proven . . O O
effective . . O O
at . . O O
reducing . . O O
mortality . . O O
from . . O O
CRC . . O O
. . . O O

Immunochemical . . O O
fecal . . O O
occult . . O O
blood . . O O
tests . . O O
facilitate . . O O
compliance . . O O
and . . O O
offer . . O O
improved . . O O
specificity . . O O
, . . O O
but . . O O
at . . O O
increased . . O O
cost . . O O
in . . O O
comparison . . O O
to . . O O
FOBT . . O O
. . . O O

Fecal . . O O
DNA . . O O
testing . . O O
may . . O O
provide . . O O
enhanced . . O O
sensitivity . . O O
for . . O O
detection . . O O
of . . O O
CRC . . O O
in . . O O
comparison . . O O
with . . O O
FOBT . . O O
, . . O O
but . . O O
its . . O O
high . . O O
cost . . O O
limits . . O O
its . . O O
use . . O O
for . . O O
generalized . . O O
screening . . O O
. . . O O

Rectal . . O O
mucin . . O O
testing . . O O
requires . . O O
additional . . O O
evaluation . . O O
to . . O O
determine . . O O
its . . O O
sensitivity . . O O
and . . O O
specificity . . O O
in . . O O
comparison . . O O
with . . O O
guaiac . . O O
- . . O O
based . . O O
FOBT . . O O
. . . O O

Serum . . O O
tests . . O O
, . . O O
such . . O O
as . . O O
proteomics . . O O
, . . O O
nuclear . . O O
matrix . . O O
proteins . . O O
, . . O O
and . . O O
serum . . O O
DNA . . O O
, . . O O
are . . O O
still . . O O
in . . O O
their . . O O
infancy . . O O
, . . O O
but . . O O
remain . . O O
a . . O O
hope . . O O
for . . O O
the . . O O
future . . O O
. . . O O

Clinicopathologic . . O O
characteristics . . O O
related . . O O
to . . O O
the . . O O
high . . O O
variability . . O O
of . . O O
coding . . O O
mononucleotide . . O O
repeat . . O O
sequences . . O O
in . . O O
tumors . . O O
with . . O O
high . . O O
- . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
. . . O O

Frameshift . . B-Mutation O
mutation . . I-Mutation B-Mutation
at . . O O
coding . . O O
mononucleotide . . O O
repeat . . O O
sequences . . O O
are . . O O
common . . O O
in . . O O
tumors . . O O
with . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
( . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
) . . O O
, . . O O
but . . O O
the . . O O
incidences . . O O
are . . O O
different . . O O
among . . O O
the . . O O
target . . O O
genes . . O O
. . . O O

We . . O O
analyzed . . O O
the . . O O
mutational . . B-Mutation B-Mutation
profiles . . O O
of . . O O
12 . . O O
known . . O O
target . . O O
genes . . O O
containing . . O O
polydeoxyadenosine . . O O
repeats . . O O
in . . O O
their . . O O
coding . . O O
sequences . . O O
in . . O O
39 . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
colorectal . . O O
carcinomas . . O O
and . . O O
40 . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
gastric . . O O
carcinomas . . O O
by . . O O
using . . O O
polymerase . . O O
chain . . O O
reaction . . O O
and . . O O
sequencing . . O O
, . . O O
and . . O O
compared . . O O
the . . O O
results . . O O
with . . O O
the . . O O
clinicopathologic . . O O
characteristics . . O O
. . . O O

Frameshift . . B-Mutation O
mutations . . I-Mutation B-Mutation
of . . O O
target . . O O
genes . . O O
in . . O O
the . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
colorectal . . O O
and . . O O
gastric . . O O
carcinomas . . O O
are . . O O
increased . . O O
according . . O O
to . . O O
the . . O O
length . . O O
of . . O O
the . . O O
polydeoxyadenosine . . O O
repeats . . O O
in . . O O
the . . O O
target . . O O
genes . . O O
. . . O O

The . . O O
mean . . O O
mutational . . B-Mutation B-Mutation
rates . . O O
of . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
colorectal . . O O
carcinomas . . O O
and . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
gastric . . O O
carcinomas . . O O
were . . O O
2 . . O O
. . . O O
03 . . O O
and . . O O
1 . . O O
. . . O O
95 . . O O
in . . O O
the . . O O
4 . . O O
genes . . O O
containing . . O O
( . . O O
A . . O O
) . . O O
10 . . O O
repeats . . O O
, . . O O
1 . . O O
. . . O O
23 . . O O
and . . O O
0 . . O O
. . . O O
73 . . O O
in . . O O
the . . O O
4 . . O O
genes . . O O
with . . O O
( . . O O
A . . O O
) . . O O
9 . . O O
repeats . . O O
and . . O O
0 . . O O
. . . O O
61 . . O O
and . . O O
0 . . O O
. . . O O
48 . . O O
in . . O O
the . . O O
4 . . O O
genes . . O O
containing . . O O
( . . O O
A . . O O
) . . O O
8 . . O O
repeats . . O O
, . . O O
respectively . . O O
( . . O O
p . . O O
< . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
. . . O O

Among . . O O
the . . O O
evaluated . . O O
clinicopathologic . . O O
findings . . O O
, . . O O
intestinal . . O O
type . . O O
gastric . . O O
carcinomas . . O O
had . . O O
more . . O O
frameshift . . B-Mutation B-Mutation
mutations . . I-Mutation I-Mutation
than . . O O
the . . O O
diffuse . . O O
type . . O O
carcinomas . . O O
( . . O O
3 . . O O
. . . O O
5 . . O O
vs . . O O
. . . O O
1 . . O O
. . . O O
9 . . O O
, . . O O
p . . O O
= . . O O
0 . . O O
. . . O O
01 . . O O
) . . O O
. . . O O

These . . O O
findings . . O O
suggest . . O O
that . . O O
mutational . . B-Mutation B-Mutation
rates . . O O
of . . O O
the . . O O
target . . O O
genes . . O O
in . . O O
MSI . . B-Mutation B-Mutation
- . . I-Mutation O
H . . I-Mutation O
tumors . . O O
are . . O O
diverse . . O O
, . . O O
and . . O O
higher . . O O
mutational . . B-Mutation B-Mutation
rates . . O O
are . . O O
related . . O O
to . . O O
the . . O O
length . . O O
of . . O O
mononucleotide . . O O
repeat . . O O
sequences . . O O
of . . O O
the . . O O
target . . O O
genes . . O O
and . . O O
histologic . . O O
type . . O O
of . . O O
tumors . . O O
. . . O O

Mutational . . O O
analysis . . O O
of . . O O
the . . O O
transforming . . O O
growth . . O O
factor . . O O
beta . . O O
receptor . . O O
type . . O O
II . . O O
gene . . O O
in . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
and . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
patients . . O O
. . . O O

Somatic . . O O
mutations . . B-Mutation B-Mutation
in . . O O
the . . O O
transforming . . O O
growth . . O O
factor . . O O
beta . . O O
receptor . . O O
type . . O O
II . . O O
( . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
) . . O O
gene . . O O
have . . O O
been . . O O
observed . . O O
in . . O O
various . . O O
human . . O O
cancers . . O O
showing . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
. . . O O

Most . . O O
of . . O O
the . . O O
mutations . . B-Mutation B-Mutation
observed . . O O
were . . O O
additions . . B-Mutation O
or . . O O
deletions . . B-Mutation O
of . . O O
the . . O O
mononucleotide . . O O
repeat . . O O
sequence . . O O
present . . O O
in . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
coding . . O O
region . . O O
, . . O O
suggesting . . O O
that . . O O
the . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
may . . O O
be . . O O
a . . O O
target . . O O
gene . . O O
of . . O O
genomic . . B-Mutation O
instability . . I-Mutation B-Mutation
in . . O O
tumorigenesis . . O O
. . . O O

Recently . . O O
, . . O O
we . . O O
reported . . O O
germ . . O O
- . . O O
line . . O O
frameshift . . B-Mutation B-Mutation
mutations . . I-Mutation I-Mutation
in . . O O
the . . O O
mononucleotide . . O O
repeat . . O O
sequence . . O O
of . . O O
the . . O O
hMSH6 . . O O
gene . . O O
, . . O O
which . . O O
is . . O O
believed . . O O
to . . O O
be . . O O
one . . O O
of . . O O
the . . O O
target . . O O
genes . . O O
of . . O O
genomic . . B-Mutation O
instability . . I-Mutation B-Mutation
in . . O O
tumorigenesis . . O O
, . . O O
suggesting . . O O
the . . O O
possibility . . O O
of . . O O
germ . . O O
- . . O O
line . . O O
mutation . . B-Mutation B-Mutation
in . . O O
mononucleotide . . O O
repeat . . O O
sequences . . O O
. . . O O

Moreover . . O O
, . . O O
one . . O O
case . . O O
of . . O O
germ . . O O
- . . O O
line . . O O
mutation . . B-Mutation B-Mutation
in . . O O
the . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
gene . . O O
was . . O O
identified . . O O
in . . O O
a . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
( . . O O
HNPCC . . O O
) . . O O
kindred . . O O
, . . O O
indicating . . O O
the . . O O
involvement . . O O
of . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
inactivation . . O O
in . . O O
tumorigenesis . . O O
of . . O O
HNPCC . . O O
. . . O O

However . . O O
, . . O O
germ . . O O
- . . O O
line . . O O
mutation . . B-Mutation B-Mutation
analysis . . O O
of . . O O
all . . O O
of . . O O
the . . O O
coding . . O O
sequences . . O O
and . . O O
the . . O O
mononucleotide . . O O
repeat . . O O
sequence . . O O
of . . O O
the . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
in . . O O
HNPCC . . O O
patients . . O O
has . . O O
not . . O O
yet . . O O
been . . O O
fully . . O O
elucidated . . O O
. . . O O

Therefore . . O O
, . . O O
to . . O O
further . . O O
investigate . . O O
the . . O O
presence . . O O
of . . O O
germ . . O O
- . . O O
line . . O O
mutations . . B-Mutation B-Mutation
, . . O O
we . . O O
screened . . O O
all . . O O
of . . O O
the . . O O
coding . . O O
region . . O O
sequences . . O O
and . . O O
mononucleotide . . O O
repeat . . O O
sequence . . O O
of . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
from . . O O
35 . . O O
HNPCC . . O O
, . . O O
44 . . O O
suspected . . O O
HNPCC . . O O
, . . O O
and . . O O
45 . . O O
sporadic . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
patients . . O O
. . . O O

However . . O O
, . . O O
no . . O O
pathogenic . . B-Mutation O
mutations . . I-Mutation B-Mutation
other . . O O
than . . O O
silent . . B-Mutation O
mutations . . I-Mutation B-Mutation
, . . O O
introgenic . . O O
mutation . . B-Mutation B-Mutation
, . . O O
and . . O O
polymorphisms . . B-Mutation B-Mutation
were . . O O
identified . . O O
. . . O O

Two . . O O
silent . . B-Mutation O
mutations . . I-Mutation B-Mutation
at . . O O
codons . . O O
309 . . O O
( . . O O
ACG . . B-Mutation O
to . . I-Mutation O
ACA . . I-Mutation O
) . . O O
and . . O O
340 . . O O
( . . O O
CAT . . B-Mutation O
to . . I-Mutation O
CAC . . I-Mutation O
) . . O O
in . . O O
the . . O O
kinase . . O O
domain . . O O
located . . O O
in . . O O
exon . . O O
4 . . O O
were . . O O
detected . . O O
. . . O O

A . . O O
1 . . O O
- . . O O
bp . . O O
cytidine . . O O
deletion . . B-Mutation B-Mutation
was . . O O
observed . . O O
6 . . O O
bases . . O O
from . . O O
the . . O O
3 . . O O
' . . O O
end . . O O
of . . O O
intron . . O O
. . . O O

Two . . O O
polymorphisms . . B-Mutation B-Mutation
were . . O O
identified . . O O
at . . O O
codon . . O O
389 . . O O
( . . O O
AAC . . B-Mutation O
to . . I-Mutation O
AAT . . I-Mutation O
) . . O O
and . . O O
at . . O O
the . . O O
fourth . . O O
- . . O O
to . . O O
- . . O O
last . . O O
base . . O O
in . . O O
intron . . O O
3 . . O O
. . . O O

The . . O O
polymorphism . . B-Mutation O
at . . O O
codon . . O O
389 . . O O
was . . O O
more . . O O
frequent . . O O
in . . O O
HNPCC . . O O
( . . O O
20 . . O O
% . . O O
; . . O O
7 . . O O
of . . O O
35 . . O O
) . . O O
and . . O O
suspected . . O O
HNPCC . . O O
patients . . O O
( . . O O
18 . . O O
% . . O O
; . . O O
8 . . O O
of . . O O
44 . . O O
) . . O O
than . . O O
in . . O O
nonmalignant . . O O
control . . O O
group . . O O
( . . O O
10 . . O O
% . . O O
; . . O O
5 . . O O
of . . O O
50 . . O O
) . . O O
. . . O O

Moreover . . O O
, . . O O
the . . O O
frequency . . O O
was . . O O
significantly . . O O
higher . . O O
in . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
patients . . O O
( . . O O
31 . . O O
% . . O O
; . . O O
14 . . O O
of . . O O
45 . . O O
) . . O O
. . . O O

This . . O O
is . . O O
the . . O O
first . . O O
report . . O O
of . . O O
a . . O O
different . . O O
frequency . . O O
of . . O O
polymorphism . . B-Mutation O
in . . O O
HNPCC . . O O
, . . O O
suspected . . O O
HNPCC . . O O
, . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
patients . . O O
, . . O O
and . . O O
healthy . . O O
normal . . O O
individuals . . O O
. . . O O

This . . O O
result . . O O
suggests . . O O
that . . O O
: . . O O
( . . O O
a . . O O
) . . O O
germ . . O O
- . . O O
line . . O O
mutation . . B-Mutation B-Mutation
of . . O O
the . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
gene . . O O
may . . O O
be . . O O
a . . O O
rare . . O O
event . . O O
during . . O O
tumorigenesis . . O O
in . . O O
HNPCC . . O O
and . . O O
sporadic . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
; . . O O
( . . O O
b . . O O
) . . O O
the . . O O
mononucleotide . . O O
repeat . . O O
sequence . . O O
of . . O O
the . . O O
TGF . . O O
- . . O O
beta . . O O
RII . . O O
gene . . O O
is . . O O
an . . O O
apparent . . O O
target . . O O
of . . O O
genomic . . B-Mutation O
instability . . I-Mutation B-Mutation
but . . O O
not . . O O
of . . O O
germ . . O O
- . . O O
line . . O O
mutation . . B-Mutation B-Mutation
; . . O O
and . . O O
( . . O O
c . . O O
) . . O O
the . . O O
polymorphism . . B-Mutation O
of . . O O
codon . . O O
389 . . O O
( . . O O
AAC . . B-Mutation O
to . . I-Mutation O
AAT . . I-Mutation O
) . . O O
is . . O O
frequent . . O O
, . . O O
especially . . O O
in . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
patients . . O O
, . . O O
in . . O O
which . . O O
it . . O O
is . . O O
more . . O O
frequent . . O O
than . . O O
in . . O O
control . . O O
group . . O O
. . . O O

Correlation . . O O
of . . O O
dynamic . . O O
contrast . . O O
- . . O O
enhanced . . O O
MRI . . O O
perfusion . . O O
parameters . . O O
with . . O O
angiogenesis . . O O
and . . O O
biologic . . O O
aggressiveness . . O O
of . . O O
rectal . . O O
cancer . . O O
: . . O O
Preliminary . . O O
results . . O O
. . . O O

# . . O O
# . . O O
PURPOSE . . O O

To . . O O
investigate . . O O
whether . . O O
quantitative . . O O
parameters . . O O
derived . . O O
from . . O O
dynamic . . O O
contrast . . O O
- . . O O
enhanced . . O O
magnetic . . O O
resonance . . O O
imaging . . O O
( . . O O
DCE . . O O
- . . O O
MRI . . O O
) . . O O
are . . O O
correlated . . O O
with . . O O
angiogenesis . . O O
and . . O O
biologic . . O O
aggressiveness . . O O
of . . O O
rectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
MATERIALS . . O O
AND . . O O
METHODS . . O O

A . . O O
total . . O O
of . . O O
46 . . O O
patients . . O O
with . . O O
rectal . . O O
cancer . . O O
underwent . . O O
DCE . . O O
- . . O O
MRI . . O O
. . . O O

Using . . O O
a . . O O
two . . O O
- . . O O
compartmental . . O O
model . . O O
, . . O O
quantitative . . O O
parameters . . O O
( . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
, . . O O
kep . . O O
, . . O O
ve . . O O
, . . O O
and . . O O
iAUC . . O O
) . . O O
were . . O O
calculated . . O O
from . . O O
the . . O O
whole . . O O
- . . O O
transverse . . O O
region . . O O
of . . O O
interest . . O O
( . . O O
ROI . . O O
) . . O O
and . . O O
high . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
area . . O O
ROI . . O O
of . . O O
entire . . O O
tumors . . O O
. . . O O

Histological . . O O
specimens . . O O
were . . O O
analyzed . . O O
for . . O O
tumor . . O O
size . . O O
; . . O O
T . . O O
/ . . O O
N . . O O
stage . . O O
; . . O O
lymphatic . . O O
, . . O O
vascular . . O O
, . . O O
perineural . . O O
invasion . . O O
; . . O O
expression . . O O
of . . O O
epidermal . . O O
growth . . O O
factor . . O O
receptor . . O O
( . . O O
EGFR . . O O
) . . O O
; . . O O
and . . O O
KRAS . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
. . . O O

Tumor . . O O
angiogenesis . . O O
was . . O O
evaluated . . O O
based . . O O
on . . O O
the . . O O
microvessel . . O O
density . . O O
( . . O O
MVD . . O O
) . . O O
and . . O O
the . . O O
expression . . O O
level . . O O
of . . O O
the . . O O
vascular . . O O
endothelial . . O O
growth . . O O
factor . . O O
. . . O O

Correlations . . O O
of . . O O
the . . O O
DCE . . O O
- . . O O
MRI . . O O
parameters . . O O
with . . O O
histological . . O O
markers . . O O
and . . O O
angiogenesis . . O O
were . . O O
determined . . O O
using . . O O
Student . . O O
' . . O O
s . . O O
t . . O O
- . . O O
test . . O O
and . . O O
analysis . . O O
of . . O O
variance . . O O
( . . O O
ANOVA . . O O
) . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
mean . . O O
kep . . O O
from . . O O
high . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
area . . O O
ROIs . . O O
showed . . O O
a . . O O
significantly . . O O
positive . . O O
correlation . . O O
with . . O O
MVD . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
030 . . O O
, . . O O
r . . O O
= . . O O
0 . . O O
. . . O O
514 . . O O
, . . O O
R . . O O
( . . O O
2 . . O O
) . . O O
= . . O O
0 . . O O
. . . O O
264 . . O O
) . . O O
. . . O O

The . . O O
mean . . O O
kep . . O O
from . . O O
the . . O O
whole . . O O
- . . O O
transverse . . O O
ROIs . . O O
showed . . O O
a . . O O
significant . . O O
inverse . . O O
correlation . . O O
with . . O O
T . . O O
stage . . O O
( . . O O
T1 . . O O
vs . . O O
. . . O O
T2 . . O O
- . . O O
4 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
021 . . O O
) . . O O
. . . O O

EGFR . . O O
- . . O O
positive . . O O
cancer . . O O
displayed . . O O
higher . . O O
mean . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
045 . . O O
) . . O O
and . . O O
kep . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
038 . . O O
) . . O O
than . . O O
EGFR . . O O
- . . O O
negative . . O O
cancer . . O O
in . . O O
whole . . O O
- . . O O
transverse . . O O
ROIs . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

These . . O O
preliminary . . O O
results . . O O
suggest . . O O
that . . O O
the . . O O
determination . . O O
of . . O O
kep . . O O
of . . O O
high . . O O
K . . O O
( . . O O
trans . . O O
) . . O O
area . . O O
permits . . O O
the . . O O
noninvasive . . O O
estimation . . O O
of . . O O
tumor . . O O
angiogenesis . . O O
in . . O O
rectal . . O O
cancer . . O O
and . . O O
that . . O O
DCE . . O O
- . . O O
MRI . . O O
parameters . . O O
can . . O O
be . . O O
used . . O O
as . . O O
imaging . . O O
biomarkers . . O O
to . . O O
predict . . O O
the . . O O
biologic . . O O
aggressiveness . . O O
of . . O O
the . . O O
tumor . . O O
and . . O O
patient . . O O
prognosis . . O O
. . . O O

Clinical . . O O
significance . . O O
of . . O O
genetic . . B-Mutation O
variations . . I-Mutation B-Mutation
in . . O O
the . . O O
PI3K . . O O
/ . . O O
PTEN . . O O
/ . . O O
AKT . . O O
/ . . O O
mTOR . . O O
pathway . . O O
in . . O O
Korean . . O O
patients . . O O
with . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVE . . O O

Signaling . . O O
through . . O O
the . . O O
PI3K . . O O
/ . . O O
PTEN . . O O
/ . . O O
AKT . . O O
/ . . O O
mTOR . . O O
pathway . . O O
is . . O O
responsible . . O O
for . . O O
balancing . . O O
cell . . O O
survival . . O O
and . . O O
apoptosis . . O O
. . . O O

Accordingly . . O O
, . . O O
the . . O O
present . . O O
study . . O O
analyzed . . O O
14 . . O O
SNPs . . B-Mutation B-Mutation
of . . O O
the . . O O
PI3K . . O O
/ . . O O
PTEN . . O O
/ . . O O
AKT . . O O
/ . . O O
mTOR . . O O
pathway . . O O
genes . . O O
and . . O O
their . . O O
impact . . O O
on . . O O
the . . O O
prognosis . . O O
for . . O O
patients . . O O
with . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

444 . . O O
consecutive . . O O
patients . . O O
with . . O O
surgically . . O O
resected . . O O
colorectal . . O O
adenocarcinoma . . O O
were . . O O
enrolled . . O O
in . . O O
the . . O O
present . . O O
study . . O O
. . . O O

The . . O O
genomic . . O O
DNA . . O O
was . . O O
extracted . . O O
from . . O O
fresh . . O O
colorectal . . O O
tissue . . O O
, . . O O
and . . O O
14 . . O O
polymorphisms . . B-Mutation B-Mutation
of . . O O
the . . O O
PI3K . . O O
/ . . O O
PTEN . . O O
/ . . O O
AKT . . O O
/ . . O O
mTOR . . O O
pathway . . O O
genes . . O O
were . . O O
determined . . O O
using . . O O
a . . O O
real . . O O
- . . O O
time . . O O
PCR . . O O
genotyping . . O O
assay . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Pathologic . . O O
stages . . O O
after . . O O
surgery . . O O
were . . O O
as . . O O
follows . . O O
: . . O O
stage . . O O
0 . . O O
/ . . O O
I . . O O
( . . O O
n . . O O
= . . O O
85 . . O O
, . . O O
19 . . O O
. . . O O
1 . . O O
% . . O O
) . . O O
, . . O O
stage . . O O
II . . O O
( . . O O
n . . O O
= . . O O
149 . . O O
, . . O O
33 . . O O
. . . O O
6 . . O O
% . . O O
) . . O O
, . . O O
stage . . O O
III . . O O
( . . O O
n . . O O
= . . O O
147 . . O O
, . . O O
33 . . O O
. . . O O
1 . . O O
% . . O O
) . . O O
, . . O O
and . . O O
stage . . O O
IV . . O O
( . . O O
n . . O O
= . . O O
63 . . O O
, . . O O
14 . . O O
. . . O O
2 . . O O
% . . O O
) . . O O
. . . O O

Univariate . . O O
and . . O O
multivariate . . O O
survival . . O O
analysis . . O O
including . . O O
stage . . O O
, . . O O
age . . O O
, . . O O
site . . O O
of . . O O
disease . . O O
, . . O O
adjuvant . . O O
chemotherapy . . O O
, . . O O
and . . O O
carcinoembryonic . . O O
antigen . . O O
( . . O O
CEA . . O O
) . . O O
level . . O O
showed . . O O
that . . O O
these . . O O
polymorphisms . . B-Mutation B-Mutation
were . . O O
not . . O O
associated . . O O
with . . O O
progression . . O O
- . . O O
free . . O O
or . . O O
overall . . O O
survival . . O O
. . . O O

For . . O O
the . . O O
clinicopathologic . . O O
parameters . . O O
, . . O O
CEA . . O O
level . . O O
and . . O O
TNM . . O O
stage . . O O
were . . O O
significant . . O O
prognostic . . O O
factors . . O O
in . . O O
a . . O O
Cox . . O O
model . . O O
for . . O O
survival . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

None . . O O
of . . O O
the . . O O
14 . . O O
SNPs . . B-Mutation B-Mutation
of . . O O
the . . O O
PI3K . . O O
/ . . O O
PTEN . . O O
/ . . O O
AKT . . O O
/ . . O O
mTOR . . O O
pathway . . O O
genes . . O O
investigated . . O O
in . . O O
this . . O O
study . . O O
was . . O O
found . . O O
to . . O O
be . . O O
an . . O O
independent . . O O
prognostic . . O O
marker . . O O
for . . O O
Korean . . O O
patients . . O O
with . . O O
surgically . . O O
resected . . O O
colorectal . . O O
cancer . . O O
. . . O O

Synchronous . . O O
colon . . O O
carcinomas . . O O
: . . O O
molecular . . O O
- . . O O
genetic . . O O
evidence . . O O
for . . O O
multicentricity . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

The . . O O
synchronous . . O O
presentation . . O O
of . . O O
multiple . . O O
colonic . . O O
adenocarcinomas . . O O
is . . O O
an . . O O
unusual . . O O
, . . O O
but . . O O
well . . O O
- . . O O
recognized . . O O
event . . O O
accounting . . O O
for . . O O
approximately . . O O
2 . . O O
- . . O O
11 . . O O
% . . O O
of . . O O
these . . O O
neoplasms . . O O
. . . O O

Synchronous . . O O
tumors . . O O
may . . O O
have . . O O
a . . O O
different . . O O
biology . . O O
and . . O O
prognosis . . O O
than . . O O
solitary . . O O
tumors . . O O
. . . O O

Evidence . . O O
based . . O O
on . . O O
measurement . . O O
of . . O O
DNA . . O O
ploidy . . O O
suggests . . O O
that . . O O
a . . O O
significant . . O O
percentage . . O O
of . . O O
synchronous . . O O
tumors . . O O
have . . O O
a . . O O
common . . O O
clonal . . O O
origin . . O O
, . . O O
probably . . O O
resulting . . O O
from . . O O
translumenal . . O O
metastasis . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

Fifteen . . O O
synchronous . . O O
colorectal . . O O
cancers . . O O
( . . O O
30 . . O O
tumors . . O O
) . . O O
were . . O O
examined . . O O
for . . O O
histologic . . O O
differences . . O O
as . . O O
well . . O O
as . . O O
genetic . . O O
mutations . . B-Mutation B-Mutation
. . . O O

p53 . . O O
gene . . O O
abnormalities . . B-Mutation O
were . . O O
detected . . O O
by . . O O
polymerase . . O O
chain . . O O
reaction . . O O
( . . O O
PCR . . O O
) . . O O
followed . . O O
by . . O O
single . . O O
- . . O O
strand . . O O
conformation . . O O
polymorphism . . O O
analysis . . O O
. . . O O

Ki . . O O
- . . O O
ras . . O O
mutations . . B-Mutation B-Mutation
were . . O O
detected . . O O
by . . O O
PCR . . O O
followed . . O O
by . . O O
oligonucleotide . . O O
- . . O O
specific . . O O
hybridization . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

p53 . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
were . . O O
detected . . O O
in . . O O
12 . . O O
of . . O O
30 . . O O
tumors . . O O
. . . O O

In . . O O
only . . O O
one . . O O
case . . O O
was . . O O
the . . O O
same . . O O
p53 . . O O
mutation . . B-Mutation B-Mutation
present . . O O
in . . O O
both . . O O
tumors . . O O
from . . O O
one . . O O
patient . . O O
. . . O O

Similarly . . O O
, . . O O
Ki . . O O
- . . O O
ras . . O O
mutations . . B-Mutation B-Mutation
were . . O O
observed . . O O
in . . O O
9 . . O O
of . . O O
30 . . O O
tumors . . O O
. . . O O

Concordant . . O O
Ki . . O O
- . . O O
ras . . O O
mutations . . B-Mutation B-Mutation
were . . O O
observed . . O O
in . . O O
only . . O O
one . . O O
case . . O O
, . . O O
which . . O O
was . . O O
also . . O O
concordant . . O O
for . . O O
p53 . . O O
mutation . . B-Mutation B-Mutation
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

Because . . O O
p53 . . O O
and . . O O
Ki . . O O
- . . O O
ras . . O O
mutations . . B-Mutation B-Mutation
tend . . O O
to . . O O
occur . . O O
fairly . . O O
early . . O O
in . . O O
tumor . . O O
development . . O O
, . . O O
it . . O O
seems . . O O
likely . . O O
that . . O O
cases . . O O
discordant . . O O
for . . O O
p53 . . O O
and . . O O
Ki . . O O
- . . O O
ras . . O O
mutations . . B-Mutation B-Mutation
represent . . O O
independently . . O O
developing . . O O
tumor . . O O
foci . . O O
. . . O O

Taken . . O O
together . . O O
, . . O O
these . . O O
findings . . O O
strongly . . O O
suggest . . O O
that . . O O
the . . O O
great . . O O
majority . . O O
of . . O O
synchronous . . O O
colonic . . O O
adenocarcinomas . . O O
arise . . O O
as . . O O
independent . . O O
neoplasms . . O O
and . . O O
their . . O O
worsened . . O O
prognosis . . O O
is . . O O
not . . O O
a . . O O
result . . O O
of . . O O
unusually . . O O
early . . O O
metastatic . . O O
spread . . O O
. . . O O

Polymorphism . . B-Mutation O
in . . O O
the . . O O
thymidylate . . O O
synthase . . O O
promoter . . O O
enhancer . . O O
region . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenomas . . O O
. . . O O

Thymidylate . . O O
synthase . . O O
( . . O O
TS . . O O
) . . O O
, . . O O
a . . O O
key . . O O
one . . O O
- . . O O
carbon . . O O
metabolizing . . O O
gene . . O O
, . . O O
encodes . . O O
an . . O O
enzyme . . O O
that . . O O
converts . . O O
dUMP . . O O
to . . O O
dTMP . . O O
, . . O O
the . . O O
rate . . O O
- . . O O
limiting . . O O
nucleotide . . O O
in . . O O
DNA . . O O
synthesis . . O O
. . . O O

We . . O O
recently . . O O
reported . . O O
that . . O O
a . . O O
promoter . . O O
polymorphism . . B-Mutation O
in . . O O
TS . . O O
modified . . O O
the . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
as . . O O
well . . O O
as . . O O
the . . O O
survival . . O O
rate . . O O
after . . O O
the . . O O
disease . . O O
. . . O O

To . . O O
explore . . O O
whether . . O O
TS . . O O
may . . O O
play . . O O
an . . O O
important . . O O
role . . O O
in . . O O
colorectal . . O O
carcinogenesis . . O O
early . . O O
in . . O O
the . . O O
multistaged . . O O
pathogenic . . O O
pathway . . O O
, . . O O
we . . O O
investigated . . O O
the . . O O
relation . . O O
between . . O O
the . . O O
TS . . O O
promoter . . O O
polymorphism . . B-Mutation O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
in . . O O
a . . O O
nested . . O O
case . . O O
- . . O O
control . . O O
study . . O O
within . . O O
the . . O O
prospective . . O O
Health . . O O
Professionals . . O O
Follow . . O O
- . . O O
up . . O O
Study . . O O
. . . O O

We . . O O
ascertained . . O O
the . . O O
TS . . O O
genotype . . O O
from . . O O
373 . . O O
incident . . O O
colorectal . . O O
adenoma . . O O
cases . . O O
and . . O O
720 . . O O
control . . O O
subjects . . O O
. . . O O

Although . . O O
there . . O O
was . . O O
no . . O O
overall . . O O
association . . O O
between . . O O
the . . O O
TS . . O O
promoter . . O O
polymorphism . . B-Mutation O
and . . O O
adenoma . . O O
risk . . O O
, . . O O
we . . O O
observed . . O O
a . . O O
significant . . O O
TS . . O O
- . . O O
alcohol . . O O
interaction . . O O
( . . O O
P . . O O
for . . O O
interaction . . O O
= . . O O
0 . . O O
. . . O O
009 . . O O
) . . O O
; . . O O
relative . . O O
to . . O O
low . . O O
alcohol . . O O
consumers . . O O
with . . O O
the . . O O
2R . . O O
/ . . O O
2R . . O O
genotype . . O O
, . . O O
those . . O O
with . . O O
high . . O O
alcohol . . O O
consumption . . O O
( . . O O
> . . O O
30 . . O O
g . . O O
/ . . O O
d . . O O
) . . O O
were . . O O
not . . O O
at . . O O
elevated . . O O
risk . . O O
if . . O O
they . . O O
had . . O O
the . . O O
2R . . O O
/ . . O O
2R . . O O
genotype . . O O
[ . . O O
relative . . O O
risk . . O O
( . . O O
RR . . O O
) . . O O
, . . O O
0 . . O O
. . . O O
80 . . O O
; . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
( . . O O
95 . . O O
% . . O O
CI . . O O
) . . O O
, . . O O
0 . . O O
. . . O O
34 . . O O
- . . O O
1 . . O O
. . . O O
90 . . O O
] . . O O
, . . O O
but . . O O
were . . O O
at . . O O
higher . . O O
risk . . O O
if . . O O
they . . O O
had . . O O
the . . O O
2R . . O O
/ . . O O
3R . . O O
genotype . . O O
( . . O O
RR . . O O
, . . O O
1 . . O O
. . . O O
70 . . O O
; . . O O
95 . . O O
% . . O O
CI . . O O
, . . O O
0 . . O O
. . . O O
87 . . O O
- . . O O
3 . . O O
. . . O O
31 . . O O
) . . O O
, . . O O
and . . O O
at . . O O
the . . O O
highest . . O O
risk . . O O
( . . O O
RR . . O O
, . . O O
3 . . O O
. . . O O
16 . . O O
; . . O O
95 . . O O
% . . O O
CI . . O O
, . . O O
1 . . O O
. . . O O
50 . . O O
- . . O O
6 . . O O
. . . O O
63 . . O O
) . . O O
if . . O O
they . . O O
had . . O O
the . . O O
3R . . O O
/ . . O O
3R . . O O
genotype . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
a . . O O
significant . . O O
interaction . . O O
was . . O O
observed . . O O
between . . O O
the . . O O
TS . . O O
promoter . . O O
polymorphism . . B-Mutation O
and . . O O
the . . O O
677C . . B-Mutation B-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
polymorphism . . I-Mutation I-Mutation
of . . O O
methylenetetrahydrofolate . . O O
reductase . . O O
( . . O O
MTHFR . . O O
; . . O O
P . . O O
for . . O O
interaction . . O O
= . . O O
0 . . O O
. . . O O
007 . . O O
) . . O O
. . . O O

These . . O O
findings . . O O
lend . . O O
additional . . O O
support . . O O
that . . O O
one . . O O
- . . O O
carbon . . O O
metabolism . . O O
is . . O O
an . . O O
important . . O O
process . . O O
in . . O O
pathogenesis . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

Colon . . O O
cancer . . O O
: . . O O
a . . O O
civilization . . O O
disorder . . O O
. . . O O

Colorectal . . O O
cancer . . O O
arises . . O O
in . . O O
individuals . . O O
with . . O O
acquired . . O O
or . . O O
inherited . . O O
genetic . . O O
predisposition . . O O
who . . O O
are . . O O
exposed . . O O
to . . O O
a . . O O
range . . O O
of . . O O
risk . . O O
factors . . O O
. . . O O

Many . . O O
of . . O O
these . . O O
risk . . O O
factors . . O O
are . . O O
associated . . O O
with . . O O
affluent . . O O
Western . . O O
societies . . O O
. . . O O

More . . O O
than . . O O
95 . . O O
% . . O O
of . . O O
colorectal . . O O
cancers . . O O
are . . O O
sporadic . . O O
, . . O O
arising . . O O
in . . O O
individuals . . O O
without . . O O
a . . O O
significant . . O O
hereditary . . O O
risk . . O O
. . . O O

Geographic . . O O
variation . . O B-Mutation
in . . O O
the . . O O
incidence . . O O
of . . O O
colorectal . . O O
cancer . . O O
is . . O O
considerable . . O O
with . . O O
a . . O O
higher . . O O
incidence . . O O
observed . . O O
in . . O O
the . . O O
West . . O O
. . . O O

Environmental . . O O
factors . . O O
contribute . . O O
substantially . . O O
to . . O O
this . . O O
variation . . O B-Mutation
. . . O O

A . . O O
number . . O O
of . . O O
these . . O O
risk . . O O
factors . . O O
are . . O O
associated . . O O
with . . O O
a . . O O
Western . . O O
lifestyle . . O O
and . . O O
could . . O O
be . . O O
considered . . O O
a . . O O
product . . O O
of . . O O
' . . O O
civilization . . O O
' . . O O
. . . O O

Recently . . O O
, . . O O
smoking . . O O
has . . O O
been . . O O
recognized . . O O
as . . O O
a . . O O
risk . . O O
factor . . O O
. . . O O

Energy . . O O
consumption . . O O
also . . O O
influences . . O O
colorectal . . O O
cancer . . O O
risk . . O O
, . . O O
with . . O O
obesity . . O O
increasing . . O O
risk . . O O
and . . O O
exercise . . O O
reducing . . O O
risk . . O O
. . . O O

However . . O O
, . . O O
the . . O O
strongest . . O O
contribution . . O O
to . . O O
environmental . . O O
risk . . O O
for . . O O
colorectal . . O O
cancer . . O O
is . . O O
dietary . . O O
. . . O O

Consumption . . O O
of . . O O
fat . . O O
, . . O O
alcohol . . O O
and . . O O
red . . O O
meat . . O O
is . . O O
associated . . O O
with . . O O
an . . O O
increased . . O O
risk . . O O
. . . O O

Fresh . . O O
fruit . . O O
and . . O O
vegetables . . O O
and . . O O
dietary . . O O
fibre . . O O
may . . O O
be . . O O
protective . . O O
. . . O O

Much . . O O
has . . O O
been . . O O
learnt . . O O
recently . . O O
about . . O O
the . . O O
molecular . . O O
pathogenesis . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

Colorectal . . O O
cancer . . O O
always . . O O
arises . . O O
in . . O O
the . . O O
context . . O O
of . . O O
genomic . . B-Mutation O
instability . . I-Mutation B-Mutation
. . . O O

There . . O O
is . . O O
inactivation . . O O
of . . O O
the . . O O
tumour . . O O
suppressor . . O O
genes . . O O
adenomatous . . O O
polyposis . . O O
coli . . O O
, . . O O
p53 . . O O
, . . O O
transforming . . O O
growth . . O O
factor . . O O
- . . O O
β . . O O
, . . O O
activation . . O O
of . . O O
oncogene . . O O
pathways . . O O
including . . O O
K . . O O
- . . O O
ras . . O O
, . . O O
and . . O O
activation . . O O
of . . O O
the . . O O
cyclooxygenase . . O O
- . . O O
2 . . O O
, . . O O
epidermal . . O O
growth . . O O
factor . . O O
receptor . . O O
and . . O O
vascular . . O O
endothelial . . O O
growth . . O O
factor . . O O
pathways . . O O
. . . O O

The . . O O
mechanisms . . O O
by . . O O
which . . O O
some . . O O
environmental . . O O
factors . . O O
modify . . O O
the . . O O
mutation . . B-Mutation B-Mutation
risk . . O O
in . . O O
these . . O O
pathways . . O O
have . . O O
been . . O O
described . . O O
. . . O O

Loss . . B-Mutation B-Mutation
of . . I-Mutation O
heterozygosity . . I-Mutation B-Mutation
on . . O O
chromosome . . O O
1 . . O O
in . . O O
sporadic . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

# . . O O
# . . O O
AIM . . O O

Loss . . B-Mutation B-Mutation
of . . I-Mutation I-Mutation
heterozygosity . . I-Mutation I-Mutation
( . . O O
LOH . . B-Mutation B-Mutation
) . . O O
on . . O O
tumor . . O O
suppressor . . O O
genes . . O O
is . . O O
believed . . O O
to . . O O
play . . O O
a . . O O
key . . O O
role . . O O
in . . O O
carcinogenesis . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

When . . O O
it . . O O
occurs . . O O
at . . O O
a . . O O
tumor . . O O
suppressor . . O O
gene . . O O
locus . . O O
with . . O O
abnormal . . B-Mutation O
allele . . I-Mutation O
, . . O O
neoplastic . . O O
transformation . . O O
happens . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
analyzed . . O O
the . . O O
LOH . . B-Mutation B-Mutation
at . . O O
21 . . O O
loci . . O O
on . . O O
chromosome . . O O
1 . . O O
in . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
to . . O O
identify . . O O
additional . . O O
loci . . O O
involved . . O O
in . . O O
colorectal . . O O
tumorigenesis . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

Twenty . . O O
- . . O O
one . . O O
polymorphic . . B-Mutation O
micro . . O O
- . . O O
satellite . . O O
DNA . . O O
markers . . O O
were . . O O
analyzed . . O O
with . . O O
PCR . . O O
both . . O O
in . . O O
83 . . O O
cases . . O O
of . . O O
colorectal . . O O
cancer . . O O
and . . O O
in . . O O
normal . . O O
tissues . . O O
. . . O O

PCR . . O O
products . . O O
were . . O O
eletrophoresed . . O O
on . . O O
an . . O O
ABI . . O O
377 . . O O
DNA . . O O
sequencer . . O O
. . . O O

Genescan . . O O
3 . . O O
. . . O O
1 . . O O
and . . O O
Genotype . . O O
2 . . O O
. . . O O
1 . . O O
software . . O O
were . . O O
used . . O O
for . . O O
LOH . . B-Mutation B-Mutation
scanning . . O O
and . . O O
analysis . . O O
. . . O O

chi2 . . O O
test . . O O
was . . O O
used . . O O
to . . O O
compare . . O O
LOH . . B-Mutation B-Mutation
frequency . . O O
with . . O O
clinicopathological . . O O
data . . O O
. . . O O

P . . O O
< . . O O
0 . . O O
. . . O O
05 . . O O
was . . O O
considered . . O O
as . . O O
statistically . . O O
significant . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
average . . O O
LOH . . B-Mutation B-Mutation
frequency . . O O
of . . O O
chromosome . . O O
1 . . O O
, . . O O
short . . O O
arm . . O O
and . . O O
long . . O O
arm . . O O
was . . O O
19 . . O O
. . . O O
83 . . O O
% . . O O
, . . O O
18 . . O O
. . . O O
00 . . O O
% . . O O
and . . O O
21 . . O O
. . . O O
66 . . O O
% . . O O
, . . O O
respectively . . O O
. . . O O

The . . O O
2 . . O O
highest . . O O
LOH . . B-Mutation B-Mutation
loci . . O O
with . . O O
a . . O O
frequency . . O O
of . . O O
36 . . O O
. . . O O
54 . . O O
% . . O O
and . . O O
32 . . O O
. . . O O
50 . . O O
% . . O O
were . . O O
identified . . O O
on . . O O
D1S468 . . O O
( . . O O
1p36 . . O O
. . . O O
33 . . O O
- . . O O
p36 . . O O
. . . O O
31 . . O O
) . . O O
and . . O O
D1S413 . . O O
( . . O O
1q31 . . O O
. . . O O
3 . . O O
) . . O O
, . . O O
respectively . . O O
. . . O O

On . . O O
D1S2726 . . O O
locus . . O O
, . . O O
LOH . . B-Mutation B-Mutation
frequency . . O O
of . . O O
rectal . . O O
cancer . . O O
was . . O O
28 . . O O
. . . O O
57 . . O O
% . . O O
( . . O O
6 . . O O
/ . . O O
21 . . O O
) . . O O
, . . O O
which . . O O
was . . O O
higher . . O O
than . . O O
that . . O O
of . . O O
colon . . O O
cancer . . O O
( . . O O
0 . . O O
. . . O O
00 . . O O
% . . O O
, . . O O
0 . . O O
/ . . O O
33 . . O O
) . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
002 . . O O
) . . O O
, . . O O
suggesting . . O O
that . . O O
the . . O O
mechanism . . O O
of . . O O
carcinogenesis . . O O
was . . O O
different . . O O
in . . O O
both . . O O
groups . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

Putative . . O O
tumor . . O O
suppressor . . O O
genes . . O O
on . . O O
chromosome . . O O
1 . . O O
may . . O O
relate . . O O
to . . O O
sporadic . . O O
colorectal . . O O
carcinomas . . O O
. . . O O

Tumor . . O O
- . . O O
suppressor . . O O
- . . O O
genes . . O O
might . . O O
locate . . O O
on . . O O
1p36 . . O O
. . . O O
33 . . O O
- . . O O
36 . . O O
. . . O O
31 . . O O
and . . O O
/ . . O O
or . . O O
1q31 . . O O
. . . O O
3 . . O O
. . . O O

[ . . O O
Assessment . . O O
of . . O O
the . . O O
risk . . O O
of . . O O
recurrence . . O O
isolated . . O O
cases . . O O
of . . O O
dominantly . . O O
inherited . . O O
diseases . . O O
with . . O O
incomplete . . O O
penetrance . . O O
and . . O O
age . . O O
- . . O O
related . . O O
dependence . . O O
] . . O O
. . . O O

A . . O O
modification . . O O
of . . O O
the . . O O
method . . O O
for . . O O
risk . . O O
estimation . . O O
in . . O O
isolated . . O O
cases . . O O
of . . O O
autosomal . . O O
dominant . . O O
disorders . . O O
with . . O O
reduced . . O O
penetrance . . O O
is . . O O
presented . . O O
. . . O O

It . . O O
is . . O O
based . . O O
on . . O O
the . . O O
Bayesian . . O O
theorem . . O O
and . . O O
considers . . O O
such . . O O
parameters . . O O
as . . O O
fitness . . O O
, . . O O
age . . O O
- . . O O
specific . . O O
expressivity . . O O
of . . O O
the . . O O
gene . . O O
and . . O O
the . . O O
effect . . O O
of . . O O
parental . . O O
age . . O O
on . . O O
mutation . . B-Mutation B-Mutation
rate . . O O
. . . O O

The . . O O
definite . . O O
expression . . O O
of . . O O
the . . O O
risk . . O O
estimation . . O O
is . . O O
proposed . . O O
. . . O O

Using . . O O
hereditary . . O O
polyposis . . O O
as . . O O
an . . O O
example . . O O
, . . O O
possible . . O O
risks . . O O
are . . O O
proposed . . O O
. . . O O

The . . O O
table . . O O
of . . O O
risks . . O O
, . . O O
depending . . O O
on . . O O
the . . O O
parental . . O O
age . . O O
, . . O O
is . . O O
given . . O O
. . . O O

[ . . O O
Colorectal . . O O
oncogenesis . . O O
] . . O O
. . . O O

Recent . . O O
progress . . O O
in . . O O
the . . O O
field . . O O
of . . O O
molecular . . O O
biology . . O O
has . . O O
allowed . . O O
us . . O O
to . . O O
identify . . O O
at . . O O
least . . O O
two . . O O
different . . O O
molecular . . O O
mechanisms . . O O
implicated . . O O
in . . O O
colorectal . . O O
carcinogenesis . . O O
( . . O O
CRC . . O O
) . . O O
: . . O O
chromosomal . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
( . . O O
CIN . . B-Mutation O
) . . O O
and . . O O
genetic . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
. . . O O

Even . . O O
though . . O O
the . . O O
two . . O O
molecular . . O O
mechanisms . . O O
differ . . O O
, . . O O
their . . O O
signalling . . O O
pathways . . O O
, . . O O
implicated . . O O
in . . O O
malignant . . O O
transformation . . O O
of . . O O
colonic . . O O
epithelial . . O O
cells . . O O
, . . O O
appear . . O O
to . . O O
be . . O O
similar . . O O
. . . O O

The . . O O
most . . O O
frequent . . O O
group . . O O
of . . O O
CRC . . O O
, . . O O
which . . O O
represents . . O O
80 . . O O
% . . O O
of . . O O
sporadic . . O O
CRC . . O O
, . . O O
is . . O O
characterized . . O O
by . . O O
allelic . . O O
losses . . B-Mutation O
on . . O O
the . . O O
short . . O O
arm . . O O
of . . O O
chromosome . . O O
17 . . O O
and . . O O
8 . . O O
and . . O O
on . . O O
the . . O O
long . . O O
arm . . O O
of . . O O
chromosome . . O O
5 . . O O
, . . O O
18 . . O O
and . . O O
22 . . O O
. . . O O

These . . O O
allelic . . O O
losses . . B-Mutation O
are . . O O
associated . . O O
with . . O O
mutations . . B-Mutation B-Mutation
in . . O O
TP53 . . O O
, . . O O
APC . . O O
, . . O O
SMAD2 . . O O
and . . O O
SMAD4 . . O O
genes . . O O
. . . O O

All . . O O
of . . O O
these . . O O
alterations . . O O
are . . O O
grouped . . O O
under . . O O
the . . O O
phenotype . . O O
CIN . . B-Mutation O
. . . O O

A . . O O
genetic . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
termed . . O O
MSI . . B-Mutation B-Mutation
( . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
) . . O O
, . . O O
which . . O O
results . . O O
from . . O O
a . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
deficiency . . O O
, . . O O
appears . . O O
in . . O O
12 . . O O
- . . O O
15 . . O O
% . . O O
of . . O O
CRC . . O O
cases . . O O
. . . O O

The . . O O
presence . . O O
of . . O O
MMR . . O O
deficiency . . O O
leads . . O O
to . . O O
the . . O O
accumulation . . O O
of . . O O
mutations . . B-Mutation B-Mutation
in . . O O
genes . . O O
controlling . . O O
cell . . O O
cycle . . O O
and . . O O
apoptosis . . O O
( . . O O
TGFBRII . . O O
, . . O O
BAX . . O O
or . . O O
CASPASE5 . . O O
) . . O O
. . . O O

More . . O O
recently . . O O
, . . O O
the . . O O
existence . . O O
of . . O O
a . . O O
third . . O O
phenotype . . O O
was . . O O
suggested . . O O
. . . O O

The . . O O
main . . O O
alteration . . O O
associated . . O O
with . . O O
this . . O O
group . . O O
of . . O O
tumors . . O O
is . . O O
the . . O O
hypermethylation . . O O
of . . O O
the . . O O
promoter . . O O
region . . O O
of . . O O
numerous . . O O
genes . . O O
, . . O O
leading . . O O
to . . O O
their . . O O
inactivation . . O O
. . . O O

An . . O O
activating . . O O
mutation . . B-Mutation B-Mutation
of . . O O
BRAF . . O O
is . . O O
frequently . . O O
associated . . O O
with . . O O
this . . O O
phenotype . . O O
. . . O O

As . . O O
described . . O O
above . . O O
, . . O O
CRC . . O O
shows . . O O
genetic . . O O
heterogeneity . . O O
, . . O O
however . . O O
the . . O O
consequences . . O O
in . . O O
terms . . O O
of . . O O
signalling . . O O
pathway . . O O
alterations . . O O
are . . O O
similar . . O O
. . . O O

For . . O O
example . . O O
, . . O O
the . . O O
activation . . O O
of . . O O
Wnt . . O O
signalling . . O O
pathways . . O O
can . . O O
result . . O O
from . . O O
the . . O O
inactivation . . O O
of . . O O
the . . O O
APC . . O O
gene . . O O
in . . O O
the . . O O
CIN . . B-Mutation O
phenotype . . O O
or . . O O
from . . O O
an . . O O
activating . . O O
mutation . . B-Mutation B-Mutation
in . . O O
the . . O O
β . . O O
- . . O O
catenin . . O O
gene . . O O
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

The . . O O
inactivation . . O O
of . . O O
TGF . . O O
β . . O O
pathways . . O O
is . . O O
also . . O O
present . . O O
in . . O O
both . . O O
tumor . . O O
types . . O O
and . . O O
is . . O O
driven . . O O
by . . O O
SMAD4 . . O O
, . . O O
and . . O O
more . . O O
rarely . . O O
by . . O O
a . . O O
SMAD2 . . O O
inactivating . . O O
mutation . . B-Mutation B-Mutation
in . . O O
CIN . . B-Mutation O
tumors . . O O
, . . O O
or . . O O
by . . O O
the . . O O
existence . . O O
of . . O O
a . . O O
frame . . B-Mutation O
- . . I-Mutation O
shift . . I-Mutation O
mutation . . I-Mutation B-Mutation
occurring . . O O
in . . O O
a . . O O
polyG . . O O
coding . . O O
track . . O O
of . . O O
the . . O O
TGF . . O O
β . . O O
( . . O O
transforming . . O O
growth . . O O
factor . . O O
) . . O O
receptor . . O O
type . . O O
II . . O O
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

The . . O O
RAS . . O O
- . . O O
MAP . . O O
kinase . . O O
pathway . . O O
is . . O O
activated . . O O
by . . O O
KRAS . . O O
mutations . . B-Mutation B-Mutation
in . . O O
CIN . . B-Mutation O
tumors . . O O
or . . O O
by . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

The . . O O
p53 . . O O
pathway . . O O
is . . O O
inactivated . . O B-Mutation
by . . O O
TP53 . . O O
inactivation . . O O
in . . O O
CIN . . B-Mutation O
tumors . . O O
or . . O O
by . . O O
BAX . . O O
inactivating . . O O
mutations . . B-Mutation B-Mutation
in . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
. . . O O

Nutritional . . O O
influences . . O O
in . . O O
selected . . O O
gastrointestinal . . O O
diseases . . O O
. . . O O

Nutritional . . O O
factors . . O O
, . . O O
as . . O O
sources . . O O
of . . O O
luminal . . O O
antigens . . O O
, . . O O
have . . O O
been . . O O
thought . . O O
to . . O O
be . . O O
important . . O O
factors . . O O
in . . O O
the . . O O
immunopathogenesis . . O O
of . . O O
numerous . . O O
gastrointestinal . . O O
diseases . . O O
. . . O O

In . . O O
some . . O O
diseases . . O O
, . . O O
the . . O O
role . . O O
of . . O O
the . . O O
nutritional . . O O
component . . O O
is . . O O
causal . . O O
in . . O O
the . . O O
susceptible . . O O
host . . O O
. . . O O

Such . . O O
diseases . . O O
include . . O O
celiac . . O O
disease . . O O
, . . O O
a . . O O
common . . O O
heritable . . O O
chronic . . O O
inflammatory . . O O
condition . . O O
of . . O O
the . . O O
small . . O O
intestine . . O O
induced . . O O
by . . O O
dietary . . O O
wheat . . O O
, . . O O
rye . . O O
and . . O O
barley . . O O
, . . O O
in . . O O
susceptible . . O O
individuals . . O O
. . . O O

Specific . . O O
HLA . . O O
- . . O O
DQ2 . . O O
and . . O O
HLA . . O O
- . . O O
DQ8 . . O O
risk . . O O
alleles . . O O
are . . O O
necessary . . O O
, . . O O
but . . O O
not . . O O
sufficient . . O O
, . . O O
for . . O O
disease . . O O
development . . O O
. . . O O

The . . O O
well . . O O
- . . O O
defined . . O O
role . . O O
of . . O O
HLA . . O O
- . . O O
DQ . . O O
heterodimers . . O O
encoded . . O O
by . . O O
these . . O O
alleles . . O O
is . . O O
to . . O O
present . . O O
cereal . . O O
peptides . . O O
to . . O O
CD4 . . O O
+ . . O O
T . . O O
cells . . O O
, . . O O
activating . . O O
an . . O O
inflammatory . . O O
immune . . O O
response . . O O
in . . O O
the . . O O
intestine . . O O
. . . O O

Genome . . O O
- . . O O
wide . . O O
association . . O O
studies . . O O
have . . O O
been . . O O
performed . . O O
which . . O O
identified . . O O
the . . O O
IL2 . . O O
- . . O O
IL21 . . O O
risk . . O O
locus . . O O
and . . O O
other . . O O
genes . . O O
with . . O O
immune . . O O
functions . . O O
and . . O O
key . . O O
roles . . O O
in . . O O
thymic . . O O
T . . O O
- . . O O
cell . . O O
selection . . O O
. . . O O

Another . . O O
example . . O O
for . . O O
this . . O O
group . . O O
is . . O O
Wilson . . O O
' . . O O
s . . O O
disease . . O O
, . . O O
an . . O O
autosomal . . O O
recessive . . O O
disorder . . O O
of . . O O
copper . . O O
metabolism . . O O
caused . . O O
by . . O O
mutation . . B-Mutation B-Mutation
of . . O O
the . . O O
ATP7B . . O O
gene . . O O
, . . O O
resulting . . O O
in . . O O
a . . O O
defect . . O O
of . . O O
biliary . . O O
copper . . O O
excretion . . O O
and . . O O
toxic . . O O
accumulation . . O O
in . . O O
the . . O O
body . . O O
, . . O O
especially . . O O
in . . O O
the . . O O
liver . . O O
, . . O O
brain . . O O
and . . O O
cornea . . O O
, . . O O
resulting . . O O
in . . O O
hepatic . . O O
and . . O O
/ . . O O
or . . O O
neurological . . O O
symptoms . . O O
. . . O O

In . . O O
other . . O O
diseases . . O O
, . . O O
however . . O O
, . . O O
the . . O O
association . . O O
is . . O O
less . . O O
well . . O O
established . . O O
. . . O O

In . . O O
such . . O O
endeavor . . O O
, . . O O
epidemiological . . O O
observations . . O O
may . . O O
become . . O O
a . . O O
valuable . . O O
part . . O O
of . . O O
the . . O O
overall . . O O
investigations . . O O
aimed . . O O
at . . O O
identifying . . O O
dietary . . O O
factors . . O O
, . . O O
which . . O O
are . . O O
involved . . O O
in . . O O
the . . O O
initiation . . O O
and . . O O
perpetuation . . O O
of . . O O
the . . O O
specific . . O O
disease . . O O
. . . O O

As . . O O
an . . O O
example . . O O
, . . O O
relationships . . O O
between . . O O
nutrition . . O O
and . . O O
colorectal . . O O
cancer . . O O
have . . O O
been . . O O
hypothesized . . O O
early . . O O
on . . O O
( . . O O
e . . O O
. . . O O
g . . O O
. . . O O
folate . . O O
, . . O O
calcium . . O O
, . . O O
vitamin . . O O
D . . O O
, . . O O
red . . O O
meat . . O O
) . . O O
. . . O O

Similarly . . O O
, . . O O
intake . . O O
of . . O O
certain . . O O
diet . . O O
constituents . . O O
like . . O O
fat . . O O
, . . O O
refined . . O O
sugar . . O O
, . . O O
fruits . . O O
, . . O O
vegetables . . O O
and . . O O
fiber . . O O
was . . O O
reported . . O O
to . . O O
be . . O O
associated . . O O
with . . O O
the . . O O
expression . . O O
of . . O O
inflammatory . . O O
bowel . . O O
diseases . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
in . . O O
children . . O O
with . . O O
active . . O O
Crohn . . O O
' . . O O
s . . O O
disease . . O O
, . . O O
enteral . . O O
nutrition . . O O
was . . O O
found . . O O
to . . O O
be . . O O
equally . . O O
effective . . O O
as . . O O
corticosteroids . . O O
in . . O O
induction . . O O
of . . O O
remission . . O O
, . . O O
with . . O O
mucosal . . O O
healing . . O O
induced . . O O
by . . O O
downregulation . . O O
of . . O O
mucosal . . O O
pro . . O O
- . . O O
inflammatory . . O O
cytokine . . O O
profiles . . O O
in . . O O
both . . O O
the . . O O
ileum . . O O
and . . O O
the . . O O
colon . . O O
after . . O O
enteral . . O O
nutrition . . O O
. . . O O

However . . O O
, . . O O
the . . O O
particular . . O O
effect . . O O
of . . O O
the . . O O
consumption . . O O
of . . O O
each . . O O
type . . O O
of . . O O
food . . O O
remains . . O O
questionable . . O O
in . . O O
most . . O O
cases . . O O
, . . O O
at . . O O
least . . O O
in . . O O
part . . O O
because . . O O
of . . O O
insufficient . . O O
data . . O O
and . . O O
serious . . O O
methodological . . O O
limitations . . O O
( . . O O
e . . O O
. . . O O
g . . O O
. . . O O
recall . . O O
bias . . O O
, . . O O
heterogeneity . . O O
between . . O O
collected . . O O
data . . O O
, . . O O
lack . . O O
of . . O O
correction . . O O
for . . O O
covariates . . O O
, . . O O
difficulties . . O O
in . . O O
double . . O O
blinding . . O O
) . . O O
. . . O O

Identification . . O O
of . . O O
mismatch . . O O
repair . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
in . . O O
young . . O O
patients . . O O
with . . O O
colorectal . . O O
cancer . . O O
and . . O O
in . . O O
patients . . O O
with . . O O
multiple . . O O
tumours . . O O
associated . . O O
with . . O O
hereditary . . O O
non . . O O
- . . O O
polyposis . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Patients . . O O
with . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
or . . O O
those . . O O
with . . O O
multiple . . O O
tumours . . O O
associated . . O O
with . . O O
hereditary . . O O
non . . O O
- . . O O
polyposis . . O O
colorectal . . O O
cancer . . O O
( . . O O
HNPCC . . O O
) . . O O
raise . . O O
suspicion . . O O
of . . O O
the . . O O
presence . . O O
of . . O O
germline . . O O
DNA . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
. . . O O

# . . O O
# . . O O
AIM . . O O

To . . O O
analyse . . O O
the . . O O
value . . O O
of . . O O
family . . O O
history . . O O
, . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
analysis . . O O
and . . O O
MMR . . O O
protein . . O O
staining . . O O
in . . O O
the . . O O
tumour . . O O
to . . O O
predict . . O O
the . . O O
presence . . O O
of . . O O
an . . O O
MMR . . O O
gene . . O O
mutation . . B-Mutation B-Mutation
in . . O O
such . . O O
patients . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

In . . O O
281 . . O O
patients . . O O
diagnosed . . O O
with . . O O
CRC . . O O
before . . O O
the . . O O
age . . O O
of . . O O
50 . . O O
years . . O O
or . . O O
with . . O O
CRC . . O O
and . . O O
at . . O O
least . . O O
one . . O O
additional . . O O
HNPCC . . O O
- . . O O
associated . . O O
cancer . . O O
, . . O O
germline . . O O
mutation . . B-Mutation B-Mutation
analysis . . O O
in . . O O
MLH1 . . O O
, . . O O
MSH2 . . O O
and . . O O
MSH6 . . O O
was . . O O
carried . . O O
out . . O O
with . . O O
denaturing . . O O
gradient . . O O
gel . . O O
electrophoresis . . O O
and . . O O
multiplex . . O O
ligation . . O O
- . . O O
dependent . . O O
probe . . O O
amplification . . O O
. . . O O

MSI . . B-Mutation B-Mutation
analysis . . O O
with . . O O
five . . O O
consensus . . O O
markers . . O O
and . . O O
MMR . . O O
protein . . O O
staining . . O O
for . . O O
MLH1 . . O O
, . . O O
MSH2 . . O O
and . . O O
MSH6 . . O O
were . . O O
carried . . O O
out . . O O
in . . O O
the . . O O
tumours . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

25 . . O O
pathogenic . . O O
mutations . . B-Mutation B-Mutation
( . . O O
8 . . O O
in . . O O
MLH1 . . O O
, . . O O
9 . . O O
in . . O O
MSH2 . . O O
and . . O O
8 . . O O
in . . O O
MSH6 . . O O
) . . O O
were . . O O
found . . O O
. . . O O

MSI . . B-Mutation B-Mutation
analysis . . O O
missed . . O O
three . . O O
and . . O O
immunohistochemistry . . O O
( . . O O
IHC . . O O
) . . O O
missed . . O O
two . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
. . . O O

Sensitivities . . O O
of . . O O
family . . O O
history . . O O
, . . O O
MSI . . B-Mutation B-Mutation
analysis . . O O
and . . O O
IHC . . O O
for . . O O
the . . O O
presence . . O O
of . . O O
a . . O O
mutation . . B-Mutation B-Mutation
were . . O O
76 . . O O
% . . O O
, . . O O
82 . . O O
% . . O O
and . . O O
88 . . O O
% . . O O
, . . O O
specificities . . O O
were . . O O
64 . . O O
% . . O O
, . . O O
70 . . O O
% . . O O
and . . O O
84 . . O O
% . . O O
, . . O O
and . . O O
positive . . O O
predictive . . O O
values . . O O
were . . O O
19 . . O O
% . . O O
, . . O O
23 . . O O
% . . O O
and . . O O
38 . . O O
% . . O O
, . . O O
respectively . . O O
. . . O O

Multivariate . . O O
analysis . . O O
showed . . O O
the . . O O
highest . . O O
odds . . O O
ratio . . O O
for . . O O
IHC . . O O
( . . O O
38 . . O O
. . . O O
3 . . O O
, . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
9 . . O O
. . . O O
0 . . O O
to . . O O
184 . . O O
) . . O O
. . . O O

Prevalence . . O O
of . . O O
pathogenic . . O O
germline . . O O
MMR . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
in . . O O
patients . . O O
with . . O O
CRC . . O O
before . . O O
the . . O O
age . . O O
of . . O O
50 . . O O
years . . O O
was . . O O
6 . . O O
% . . O O
and . . O O
in . . O O
those . . O O
with . . O O
> . . O O
or . . O O
= . . O O
2 . . O O
HNPCC . . O O
- . . O O
associated . . O O
tumours . . O O
was . . O O
22 . . O O
% . . O O
. . . O O

In . . O O
the . . O O
second . . O O
group . . O O
, . . O O
no . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
were . . O O
found . . O O
among . . O O
the . . O O
29 . . O O
patients . . O O
who . . O O
were . . O O
diagnosed . . O O
with . . O O
their . . O O
first . . O O
tumour . . O O
after . . O O
the . . O O
age . . O O
of . . O O
60 . . O O
years . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

Family . . O O
history . . O O
, . . O O
MSI . . B-Mutation B-Mutation
analysis . . O O
and . . O O
IHC . . O O
are . . O O
indicative . . O O
parameters . . O O
to . . O O
select . . O O
patients . . O O
with . . O O
CRC . . O O
for . . O O
MMR . . O O
gene . . O O
mutation . . B-Mutation B-Mutation
analysis . . O O
. . . O O

The . . O O
data . . O O
show . . O O
that . . O O
IHC . . O O
is . . O O
the . . O O
best . . O O
single . . O O
selection . . O O
criterion . . O O
. . . O O
